Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone Mineral Density

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    328 result(s) found for: Bone Mineral Density. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004316-73 Sponsor Protocol Number: 3189 Start Date*: 2006-08-23
    Sponsor Name:Royal Liverpool University hospital
    Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ...
    Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004765-42 Sponsor Protocol Number: CZOL446GGB12 including amd 1 Start Date*: 2006-05-03
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation T...
    Medical condition: Decreased bone mineral density in prostate cancer patients being treated with ADT
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003539-37 Sponsor Protocol Number: CZOL446H2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis
    Full Title: An international, multicenter, randomized, open-label, parallel efficacy, and safety trial of intravenous zoledronic acid compared to intravenous pamidronate in children with severe osteogenesis im...
    Medical condition: Osteogenesis Imperfecta
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-016783-37 Sponsor Protocol Number: WS475202 Start Date*: 2010-01-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: The Effects of 18-Month Replacement with a Very Low Fixed Dose vs. Standard Dose of Growth Hormone (GH) on Insulin Sensitivity, Body Composition, Bone Mass, Lipids, Muscle Strength and Quality of L...
    Medical condition: Growth hormone deficiency in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002831-14 Sponsor Protocol Number: CZOL446GDE13 Start Date*: 2005-06-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor negative breast cancer and adjuvant chemotherapeutic treatment
    Medical condition: Primary, hormonreceptor negative breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013777-17 Sponsor Protocol Number: 1 Start Date*: 2010-02-08
    Sponsor Name:Central Manchester and Manchester University Children's Hospital NHS Trust. [...]
    1. Central Manchester and Manchester University Children's Hospital NHS Trust.
    2.
    Full Title: The effect of pamidronate treatment on bone health in patients with neuromuscular disease undergoing hip surgery.
    Medical condition: Children with neuromuscular conditions undergoing hip surgery. Aiming to identify whether pamidronate a licenced medicine mainatins bone mineral density in patients with neuromuscular conditions un...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004104-30 Sponsor Protocol Number: 307-MET-9002-0009 Start Date*: 2015-04-01
    Sponsor Name:Pharmacia & Upjohn S.A.
    Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety
    Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002887-29 Sponsor Protocol Number: Uni-Koeln-1574 Start Date*: 2013-02-13
    Sponsor Name:University of Cologne
    Full Title: Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab
    Medical condition: In this study we will evaluate the efficacy of Denosumab in children with Osteogenesis imperfecta. Subjects will be treated every 12 weeks over 36 weeks with Denosumab 1mg/kg body weight s.c.. Effi...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002418-12 Sponsor Protocol Number: CFEM345D2407 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early brea...
    Medical condition: Bone loss attributed to cessation of ovarian estrogen production is common in postmenopausal women. In postmenopausal women with breast cancer, treatment with an aromatase inhibitor may further red...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019758-42 Sponsor Protocol Number: I2M-MC-GSDB Start Date*: 2010-11-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women with Low Bone Mineral Density: An Evaluation of the Dose Response Relationship using Bone Mineral Density
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10031282 Osteoporosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Completed) EE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001666-40 Sponsor Protocol Number: CZOL446H2202E1 Start Date*: 2005-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe...
    Medical condition: Osteogenesis Imperfecta
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002811-27 Sponsor Protocol Number: OI-2011 Start Date*: 2011-11-07
    Sponsor Name:Bente Langdahl, consultant, ass. professor, PhD, DMSc
    Full Title: The Effect of Treatment with PTH and Zoledronic acid in Patients with Osteogenesis Imperfecta
    Medical condition: Osteogenesis imperfecta
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002349-12 Sponsor Protocol Number: RALBAT Start Date*: 2013-08-17
    Sponsor Name:Unit of Infectious Diseases, Department of Medical Scieces, University of Torino c/o ASLTO2, Amedeo di Savoia Hospital
    Full Title: “Switching HIV-positive Women With Undetectable Viremia on Tenofovir/Emtricitabine plus Boosted Atazanavir to RALtegravir (400 mg twice-daily) plus Boosted ATazanavir (300/100 mg once-daily): A Pil...
    Medical condition: HIV infection, osteopenia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000431-40 Sponsor Protocol Number: UF9672 Start Date*: 2016-05-19
    Sponsor Name:Health Ministry
    Full Title: Randomized controlled study evaluating the effect of a biotherapy treatment (anti-RANKL ligand antibody: Denosumab) on bone and vascular metabolism in osteoporotic chronic kidney disease
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10009119 Chronic renal failure LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001716-23 Sponsor Protocol Number: 452622 Start Date*: 2007-12-03
    Sponsor Name:Southampton University Hospitals NHS Trust
    Full Title: A Double-Blind Randomised Placebo-Controlled Trial of Vitamin D Supplements for Pregnant Women with Low Levels of Vitamin D in Early Pregnancy
    Medical condition: Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005991 Bone mass decreased LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-000547-85 Sponsor Protocol Number: OSTEODOLU Start Date*: 2013-09-03
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY
    Medical condition: HIV-infected patients with low bone mineral density
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10020175 HIV infection with other conditions LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005040-35 Sponsor Protocol Number: 0120 Start Date*: 2021-01-28
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of effervescent and buffered alendronate on bone turnover compared to conventional alendronate: A randomized non-inferiority trial
    Medical condition: Osteopenia, i.e. bone mineral density T-score < -1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10005991 Bone mass decreased LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001650-26 Sponsor Protocol Number: ZOL6700 Start Date*: 2019-10-25
    Sponsor Name:Hospital South West Jutland
    Full Title: Zoledronic acid for prevention of bone loss after bariatric surgery
    Medical condition: Morbid obese subjects undergoing bariatric surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009155-37 Sponsor Protocol Number: 2008/066/HP Start Date*: 2010-09-07
    Sponsor Name:CHU-HOPITAUX DE ROUEN
    Full Title: Evaluation of the impact of physical reconditioning associated with specific nutritional supplementation in obese patients suffering of metabolic syndrome.
    Medical condition: Obese patients suffering of metabolic syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA